Market Research Logo
Region: Africa
Category: Country Overviews

Africa Country Overviews

(81 reports matching your criteria)
  • Ghana Pharmaceuticals & Healthcare Q4 2018

    ... has led to difficulties doingbusiness, including high operational costs for foreign companies. While Ghana is positioned as one of the more attractivepharmaceutical markets for multinational firms on a regional basis, generic products will maintain a ... Read More

  • Sub-Saharan Africa Pharmaceuticals & Healthcare Q4 2018

    ... within the generic medicines sector, while the larger, moredeveloped markets present viable opportunities for patented medicine sales in urban regions. Cooperative agreements withinternational firms will provide opportunities for domestic firms to expand their manufacturing capacities. Read More

  • Algeria Pharmaceuticals & Healthcare Q1 2019

    ... and healthcare industries willcontinue to create investment opportunities, despite the slow progress in improving the regulatory environment. Despite sustaineddevelopment of local drug manufacturing capacity - which is in part driven by foreign direct investment and ... Read More

  • Cameroon Pharmaceuticals & Healthcare Q1 2019

    ... Although the health system and pharmaceutical sector willcontinue to gradually develop, low spending per capita on medicine and a poor operating environment will continue to weigh onopportunities presented to drugmakers in the short term. The ... Read More

  • Uganda Pharmaceuticals & Healthcare Q4 2018

    ... remain dominant, while the government plans to localisedrug production to boost medicine sustainability. While the market has brighter long-term prospects, multinational drugmakerappetite will remain subdued despite the positive economic growth forecast over the coming years. Read More

  • Kenya Pharmaceuticals & Healthcare Q1 2019

    ... or distributors. Authorities are also investing in regulatoryimprovement initiatives, which will complement their efforts to achieve universal healthcare coverage. On the other hand, someforeign players may remain weary of committing to the market due to ... Read More

  • Namibia Pharmaceuticals & Healthcare Q4 2018

    ... and efficiency issues within the public healthcare sector. The small middle-and upper-class segments provide pockets of demand for innovative medicines, which will continue to be imported by key regionalplayers and representative offices of established multinationals. Read More

  • Zimbabwe Pharmaceuticals & Healthcare Q4 2018

    ... multinational drugmakers are deterred by thechallenging macroeconomic environment. Achieving self-sufficiency in the sector will require currency regime reform; however, itremains unclear which new regime they will adopt. This creates uncertain conditions in Zimbabwe's pharmaceutical market ... Read More

  • Gabon Pharmaceuticals & Healthcare Q4 2018

    ... by factors including modest but growingpopulation numbers, high prevalence of infectious diseases and the growing burden of civilisation diseases. However, given thetight funding environment, most of the commercial opportunities remain limited to the generics sector. Read More

  • Tunisia Pharmaceuticals & Healthcare Q4 2018

    ... will challenge foreign investment into the sector.Highlighting the market's longer-term potential, some multinational drugmakers have shown their willingness to do business in thecountry, though the majority choose to operate indirectly to minimise the risks involved. Read More

  • Botswana Pharmaceuticals & Healthcare Q4 2018

    ... healthcare. Medicine sales will be limited by weakregulatory framework, a small pensionable population and a highly ruralised community. Despite a potential for growth in theunderdeveloped sector, multinational drugmakers will favour larger markets in the region ... Read More

  • Nigeria Pharmaceuticals & Healthcare Q4 2018

    ... opportunities are supported by robust fundamentals such as a large market size and expandingpopulation. The majority of multinational drugmakers will continue to opt for an indirect presence as the business climate remainsdecidedly difficult in Nigeria. Read More

  • Mauritius Pharmaceuticals & Healthcare Q4 2018

    ... moderately greater spending power than its peers in Sub-SaharanAfrica, Mauritius’ per capita medicine expenditure will remain well below the purchasing power of developed markets. On the upside,the business environment will remain relatively strong, while Mauritius' ... Read More

  • Mozambique Pharmaceuticals & Healthcare Q4 2018

    ... diseases and improving the country'soverall health standing, poor regulatory framework and a fragmented healthcare system will limit patient access to qualitymedicines. Furthermore, ongoing political and economic risks cause us to view Mozambique as one of ... Read More

  • Morocco Pharmaceuticals & Healthcare Q4 2018

    ... treatments. Although the government'scommitment to improving healthcare via the expansion of health insurance coverage will be a significant factor for future medicinesales growth, we believe generics drugmakers will be the main beneficiaries as the state ... Read More

  • Tanzania Pharmaceuticals & Healthcare Q4 2018

    ... limited by low per capita spending on medicines andan underdeveloped healthcare sector. Whilst demand for medicine will increase over the long-term, driven by the country’s rapidlyexpanding population and high disease burden, we expect that Tanzania's ... Read More

  • Ethiopia Pharmaceuticals & Healthcare Q4 2018

    ... government is strongly committed to improvingthe operating environment to attract foreign investment, particularly from China, which combined with a budding manufacturingsector bodes well for foreign drugmaker appetite. Over the near-term, multinational drugmaker investment in the ... Read More

  • Angola Pharmaceuticals & Healthcare Q4 2018

    ... training doctors and nurses, weakening the pharmaceutical andhealthcare sectors. Angola’s new President, João Lourenço, has pledged to combat corruption, attract foreign investment andimprove healthcare services. However, we continue to view Angola as one of the ... Read More

  • Sudan and South Sudan Pharmaceuticals & Healthcare Q4 2018

    ... of commercial incentives limit multinational drugmaker interest in the market.Positive fundamentals in the form of a rising chronic disease burden and large population bode well for long-term opportunities,however, the elevated industry-and-operational risks will undermine any ... Read More

  • CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Morocco

    ... information and analysis on the healthcare, regulatory and reimbursement landscape in Morocco. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Morocco. ... Read More

  • Cote d'Ivoire Pharmaceuticals & Healthcare Q4 2018

    ... advantage, key factors such as limited access tomedicines and a lack of healthcare infrastructure will limit commercial opportunities. We hold a more positive long-term outlook onthe back of economic prosperity and the push for healthcare ... Read More

  • Angola Pharmaceuticals & Healthcare Report Q3 2018

    ... demographic, per capita spending on medicines will remainsignificantly low over our forecast period. However, overall growth of the market will be supported by a rapidly growing populationcoupled with small but steady improvements to healthcare access ... Read More

  • Zambia Pharmaceuticals & Healthcare Report Q3 2018

    ... However, few opportunities exist from the perspective ofmultinational companies, given factors such as the low purchasing power and the wide-spread presence of counterfeit medicines.On the other hand, authorities' support for the reduction of reliance on ... Read More

  • Algeria Pharmaceuticals & Healthcare Report Q3 2018

    ... years. Algeria’s strategic geographicalposition and government incentives for investors will support the country’s long-term aspiration towards becoming a drugmanufacturing and export base. That said, slow progress in revising drug pricing regulations and import restrictions will ... Read More

  • Zimbabwe Pharmaceuticals & Healthcare Q2 2018

    ... thepublic healthcare sector received only minor contributions from the government, partly a result of growing public debt. Followingthe successful replacement of Mugabe with the more reform-minded President Emmerson Mnangagwa in late 2017, we hold amore ... Read More

< prev 1 3 4